News headlines about EDAP TMS (NASDAQ:EDAP) have been trending positive on Saturday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. EDAP TMS earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 44.8170045186519 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
EDAP has been the topic of several recent research reports. Zacks Investment Research cut shares of EDAP TMS from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 29th. HC Wainwright reiterated a “buy” rating and set a $6.50 target price on shares of EDAP TMS in a report on Friday, August 25th. Finally, ValuEngine cut shares of EDAP TMS from a “hold” rating to a “sell” rating in a report on Friday, September 1st.
EDAP TMS (NASDAQ:EDAP) traded down 2.31% during mid-day trading on Friday, hitting $2.96. 47,575 shares of the stock were exchanged. The company has a 50 day moving average of $3.06 and a 200 day moving average of $2.96. The firm’s market cap is $85.83 million. EDAP TMS has a 12-month low of $2.25 and a 12-month high of $3.85.
EDAP TMS (NASDAQ:EDAP) last released its quarterly earnings data on Wednesday, August 23rd. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.03). EDAP TMS had a negative net margin of 0.27% and a positive return on equity of 10.31%. The company had revenue of $10.40 million for the quarter, compared to analyst estimates of $10.00 million. During the same quarter in the prior year, the firm earned $0.10 EPS. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. On average, equities analysts anticipate that EDAP TMS will post $0.01 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Positive Press Coverage Somewhat Unlikely to Affect EDAP TMS (NASDAQ:EDAP) Share Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/edap-tms-edap-earning-positive-press-coverage-analysis-shows.html.
About EDAP TMS
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
Receive News & Ratings for EDAP TMS S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EDAP TMS S.A. and related companies with MarketBeat.com's FREE daily email newsletter.